cabozantinib

Exelixis, Inc. announced the promotion of Dana T. Aftab, Ph.D., to Executive Vice President, Research and Development. Aftab, with 25 years at Exelixis, will lead drug discovery, translational research, product development, and medical affairs. She played a critical role in developing CABOMETYX® (cabozantinib). The company aims to maximize its portfolio, including zanzalintinib. Amy Peterson, M.D., previously Executive Vice President, Product Development & Medical Affairs, has left Exelixis. Exelixis is focused on creating next-generation oncology medicines.

Arcus Biosciences’ shares surged after promising Phase 1/1b data for its casdatifan-cabozantinib combo in clear cell renal cell carcinoma (ccRCC. The ARC-20 study showed a 46% confirmed overall response rate, exceeding historic benchmarks. Arcus plans Phase 3 trials (PEAK-1) and others evaluating the combination in various ccRCC treatment settings. The positive results highlight the potential to change standards of care for patients whose ccRCC has advanced despite prior immunotherapy treatment.